3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Voltage-Gated Calcium Channels and α-Synuclein: Implications in Parkinson’s Disease

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alpha-synuclein (α-syn) is biochemically and genetically linked to Parkinson’s disease (PD) and other synucleinopathies. It is now widely accepted that α-syn can be released in the extracellular space, even though the mechanism of its release is still unclear. In addition, pathology-related aggregated species of α-syn have been shown to propagate between neurons in synaptically connected areas of the brain thereby assisting the spreading of pathology in healthy neighboring neuronal cells. In neurons, calcium channels are key signaling elements that modulate the release of bioactive molecules (hormones, proteins, and neurotransmitters) through calcium sensing. Such calcium sensing activity is determined by the distinct biophysical and pharmacological properties and the ability of calcium channels to interact with other modulatory proteins. Although the function of extracellular α-syn is currently unknown, previous work suggested the presence of a calcium-dependent mechanism for α-syn secretion both in vitro, in neuronal cells in culture, and also in vivo, in the context of a trans-neuronal network in brain. Mechanisms regulating extracellular α-syn levels may be of particular importance as they could represent novel therapeutic targets. We discuss here how calcium channel activity may contribute to α-syn aggregation and secretion as a pathway to disease progression in synucleinopathies.

          Related collections

          Most cited references47

          • Record: found
          • Abstract: found
          • Article: not found

          'Rejuvenation' protects neurons in mouse models of Parkinson's disease.

          Why dopamine-containing neurons of the brain's substantia nigra pars compacta die in Parkinson's disease has been an enduring mystery. Our studies suggest that the unusual reliance of these neurons on L-type Ca(v)1.3 Ca2+ channels to drive their maintained, rhythmic pacemaking renders them vulnerable to stressors thought to contribute to disease progression. The reliance on these channels increases with age, as juvenile dopamine-containing neurons in the substantia nigra pars compacta use pacemaking mechanisms common to neurons not affected in Parkinson's disease. These mechanisms remain latent in adulthood, and blocking Ca(v)1.3 Ca2+ channels in adult neurons induces a reversion to the juvenile form of pacemaking. Such blocking ('rejuvenation') protects these neurons in both in vitro and in vivo models of Parkinson's disease, pointing to a new strategy that could slow or stop the progression of the disease.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The Synucleinopathies: Twenty Years On

            In 2017, it is two hundred years since James Parkinson provided the first complete clinical description of the disease named after him, fifty years since the introduction of high-dose D,L-DOPA treatment and twenty years since α-synuclein aggregation came to the fore. In 1998, multiple system atrophy joined Parkinson’s disease and dementia with Lewy bodies as the third major synucleinopathy. Here we review our work, which led to the identification of α-synuclein in Lewy bodies, Lewy neurites and Papp-Lantos bodies, as well as what has happened since. Some of the experiments described were carried out in collaboration with ML Schmidt, JQ Trojanowski and VMY Lee.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Targeting voltage-gated calcium channels in neurological and psychiatric diseases.

              Voltage-gated calcium channels are important regulators of brain, heart and muscle functions, and their dysfunction can give rise to pathophysiological conditions ranging from cardiovascular disorders to neurological and psychiatric conditions such as epilepsy, pain and autism. In the nervous system, calcium channel blockers have been used successfully to treat absence seizures, and are emerging as potential therapeutic avenues for pathologies such as pain, Parkinson disease, addiction and anxiety. This Review provides an overview of calcium channels as drug targets for nervous system disorders, and discusses potential challenges and opportunities for the development of new clinically effective calcium channel inhibitors.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Mol Neurosci
                Front Mol Neurosci
                Front. Mol. Neurosci.
                Frontiers in Molecular Neuroscience
                Frontiers Media S.A.
                1662-5099
                09 October 2019
                2019
                : 12
                : 237
                Affiliations
                [1] 1Center for Basic Research, Biomedical Research Foundation Academy of Athens , Athens, Greece
                [2] 2Laboratory of Biochemistry, Department of Chemistry, National and Kapodistrian University of Athens , Athens, Greece
                Author notes

                Edited by: Tiago F. Outeiro, University Medical Center Göttingen, Germany

                Reviewed by: Charles Robert Harrington, University of Aberdeen, United Kingdom; Diana Fernandes Lázaro, University Medical Center Göttingen, Germany

                *Correspondence: Kostas Vekrellis, vekrellis@ 123456bioacademy.gr
                Evangelia Emmanouilidou, eemman@ 123456chem.uoa.gr
                Article
                10.3389/fnmol.2019.00237
                6794345
                31649506
                fc09c253-b2c8-4ea9-980f-dfcb7db41c52
                Copyright © 2019 Leandrou, Emmanouilidou and Vekrellis.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 15 July 2019
                : 17 September 2019
                Page count
                Figures: 1, Tables: 1, Equations: 0, References: 54, Pages: 7, Words: 0
                Funding
                Funded by: General Secretariat for Research and Technology 10.13039/501100003448
                Award ID: ELIDEK 1065
                Categories
                Neuroscience
                Mini Review

                Neurosciences
                alpha-synuclein,parkinson’s and related diseases,protein aggregation,secretion,calcium,voltage gated ca2+ channel,neurodegeneration

                Comments

                Comment on this article